Singapore approves Gilead's remdesivir for COVID-19 treatment

FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (COVID-19), during the outbreak of the coronavirus disease (COVID-19), in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo

SINGAPORE (Reuters) – Singapore’s Health Sciences Authority said on Wednesday it granted conditional approval for Gilead Sciences Inc’s antiviral drug remdesivir for the treatment of some patients with COVID-19 infection.

South Korea, Japan, India and the United States have also approved the drug for emergency use.

Reporting by Aradhana Aravindan and John Geddie in Singapore, editing by Louise Heavens

Our Standards:The Thomson Reuters Trust Principles.